skip to content

Roche's Kadcyla is the first targeted therapy to show significant overall survival benefit in people with HER2-positive early-stage breast cancer with residual invasive disease after neoadjuvant treatment

Media

Media releases
view all

stay updated

get the latest news and updates to your inbox.